Prediction of paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cells

Breast Cancer Research

Volumn 11, Issue 1, 2009, Pages

  Nakayama, Satoshi ^a   Torikoshi, Yasuhiro ^a   Takahashi, Takeshi ^b   Yoshida, Tomokazu ^a   Sudo, Tamotsu ^b   Matsushima, Tomoko ^a   Kawasaki, Yuko ^a   Katayama, Aya ^a   Gohda, Keigo ^a   Hortobagyi, Gabriel N ^b   Noguchi, Shinzaburo ^c   Sakai, Toshiyuki ^d   Ishihara, Hideki ^a   Ueno, Naoto T ^b  

^a SYSMEX CORPORATION   (Japan)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; PACLITAXEL; PLACEBO; ANTINEOPLASTIC AGENT; DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL STRAIN MCF 7; CELL VIABILITY; CHROMATIN STRUCTURE; CONTROLLED STUDY; DNA STRUCTURE; DRUG EFFICACY; DRUG SENSITIVITY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PROTEIN EXPRESSION; TREATMENT OUTCOME; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; BREAST TUMOR; CELL CYCLE; CHROMATIN; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; ENZYMOLOGY; GENETICS; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; TUMOR CELL CULTURE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CDC2 PROTEIN KINASE; CELL CYCLE; CHROMATIN; CYCLIN-DEPENDENT KINASE 2; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; PACLITAXEL; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 67549101433     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2231     Document Type: Article

References (30)

1. Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK, Hortobagyi GN. Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991, 83:1797-1805. 10.1093/jnci/83.24.1797-a, 1683908.
2. Nabholtz JM, Gelmon K, Bontenbal M, Spielmann M, Catimel G, Conte P, Klaassen U, Namer M, Bonneterre J, Fumoleau P, Winograd B. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 1996, 14:1858-1867.
3. Bishop JF, Dewar J, Toner GC, Smith J, Tattersall MH, Olver IN, Ackland S, Kennedy I, Goldstein D, Gurney H, Walpole E, Levi J, Stephenson J, Canetta R. Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J Clin Oncol 1999, 17:2355-2364.
4. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003, 21:1431-1439. 10.1200/JCO.2003.09.081, 12668651.
5. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Cooper MR, Hayes DF, Tkaczuk KH, Fleming G, Holland JF, Duggan DB, Carpenter JT, Frei E, Schilsky RL, Wood WC, Muss HB, Norton L. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003, 21:976-983. 10.1200/JCO.2003.02.063, 12637460.
6. Mamounas EP, Bryant J, Lembersky B, Fehrenbacher L, Sedlacek SM, Fisher B, Wickerham DL, Yothers G, Soran A, Wolmark N. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 2005, 23:3686-3696. 10.1200/JCO.2005.10.517, 15897552.
7. Blagosklonny MV, Giannakakou P, el-Deiry WS, Kingston DG, Higgs PI, Neckers L, Fojo T. Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death. Cancer Res 1997, 57:130-135.
8. Blagosklonny MV, Schulte T, Nguyen P, Trepel J, Neckers LM. Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Res 1996, 56:1851-1854.
9. Yu D, Liu B, Jing T, Sun D, Price JE, Singletary SE, Ibrahim N, Hortobagyi GN, Hung MC. Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to Taxol. Oncogene 1998, 16:2087-2094. 10.1038/sj.onc.1201729, 9572489.
10. Giannakakou P, Sackett DL, Kang YK, Zhan Z, Buters JT, Fojo T, Poruchynsky MS. Paclitaxel-resistant human ovarian cancer cells have mutant β-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 1997, 272:17118-17125. 10.1074/jbc.272.27.17118, 9202030.
11. Sève P, Mackey J, Isaac S, Trédan O, Souquet PJ, Pérol M, Lai R, Voloch A, Dumontet C. Class III β-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther 2005, 4:2001-2007. 10.1158/1535-7163.MCT-05-0244, 16373715.
12. Yu D. Mechanisms of ErbB2-mediated paclitaxel resistance and trastuzumab-mediated paclitaxel sensitization in ErbB2-overexpressing breast cancers. Semin Oncol 2001, 28(5 Suppl 16):12-17. 10.1016/S0093-7754(01)90277-5, 11706391.
13. Andre F, Hatzis C, Anderson K, Sotiriou C, Mazouni C, Mejia J, Wang B, Hortobagyi GN, Symmans WF, Pusztai L. Microtubule-associated protein tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer. Clin Cancer Res 2007, 13:2061-2067. 10.1158/1078-0432.CCR-06-2078, 17404087.
14. Sudo T, Nitta M, Saya H, Ueno NT. Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint. Cancer Res 2004, 64:2502-2508. 10.1158/0008-5472.CAN-03-2013, 15059905.
15. Nigg EA. Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol 2001, 2:21-32. 10.1038/35048096, 11413462.
16. Meikrantz W, Schlegel R. Suppression of apoptosis by dominant negative mutants of cyclin-dependent protein kinases. J Biol Chem 1996, 271:10205-10209. 10.1074/jbc.271.17.10205, 8626584.
17. Shen SC, Huang TS, Jee SH, Kuo ML. Taxol-induced p34cdc2 kinase activation and apoptosis inhibited by 12-O-tetradecanoylphorbol-13-acetate in human breast MCF-7 carcinoma cells. Cell Growth Differ 1998, 9:23-29.
18. Wang TH, Wang HS, Soong YK. Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer 2000, 88:2619-2628. 10.1002/1097-0142(20000601)88:11<2619::AID-CNCR26>3.0.CO;2-J, 10861441.
19. Arriola E, Moreno A, Varela M, Serra JM, Falo C, Benito E, Escobedo AP. Predictive value of HER-2 and topoisomerase IIα in response to primary doxorubicin in breast cancer. Eur J Cancer 2006, 42:2954-2960. 10.1016/j.ejca.2006.06.013, 16935488.
20. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M, Henderson IC. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994, 330:1260-1266. 10.1056/NEJM199405053301802, 7908410.
21. van Diest PJ, Wall E, Baak JP. Prognostic value of proliferation in invasive breast cancer: a review. J Clin Pathol 2004, 57:675-681. 10.1136/jcp.2003.010777, 1770351, 15220356.
22. Potemski P, Kusinska R, Watala C, Pluciennik E, Bednarek AK, Kordek R. Cyclin E expression in breast cancer correlates with negative steroid receptor status, HER2 expression, tumor grade and proliferation. J Exp Clin Cancer Res 2006, 25:59-64.
23. Morgan DO. Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu Rev Cell Dev Biol 1997, 13:261-291. 10.1146/annurev.cellbio.13.1.261, 9442875.
24. Dougherty MK, Schumaker LM, Jordan VC, Welshons WV, Curran EM, Ellis MJ, El-Ashry D. Estrogen receptor expression and sensitivity to paclitaxel in breast cancer. Cancer Biol Ther 2004, 3:460-467.
25. Ishihara H, Yoshida T, Kawasaki Y, Kobayashi H, Yamasaki M, Nakayama S, Miki E, Shohmi K, Matsushima T, Tada S, Torikoshi Y, Morita M, Tamura S, Hino Y, Kamiyama J, Sowa Y, Tsuchihashi Y, Yamagishi H, Sakai T. A new cancer diagnostic system based on a CDK profiling technology. Biochim Biophys Acta 2005, 1741:226-233.
26. Wehland J, Henkart M, Klausner R, Sandoval IV. Role of microtubules in the distribution of the Golgi apparatus: effect of taxol and microinjected anti-α-tubulin antibodies. Proc Natl Acad Sci USA 1983, 80:4286-4290. 10.1073/pnas.80.14.4286, 384022, 6136036.
27. Hasegawa Y, Goto M, Hanai N, Ijichi K, Adachi M, Terada A, Hyodo I, Ogawa T, Furukawa T. Evaluation of optimal drug concentration in histoculture drug response assay in association with clinical efficacy for head and neck cancer. Oral Oncol 2007, 43:749-756. 10.1016/j.oraloncology.2006.09.003, 17112769.
28. Ohie S, Udagawa Y, Kozu A, Komuro Y, Aoki D, Nozawa S, Moossa AR, Hoffman RM. Cisplatin sensitivity of ovarian cancer in the histoculture drug response assay correlates to clinical response to combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide. Anticancer Res 2000, 20:2049-2054.
29. Jänicke RU, Sprengart ML, Wati MR, Porter AG. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 1998, 273:9357-9360. 10.1074/jbc.273.16.9357, 9545256.
30. Lu KH, Lue KH, Chou MC, Chung JG. Paclitaxel induces apoptosis via caspase-3 activation in human osteogenic sarcoma cells (U-2 OS). J Orthop Res 2005, 23:988-994. 10.1016/j.orthres.2005.01.018, 16140185.